scholarly journals Aqueous extract of bitter leaf Vernonia amygdalina Delile (Asterales: Asteraceae) ameliorates testosterone-induced benign prostatic hyperplasia (BPH) in Wistar rats

2017 ◽  
Vol 4 (7) ◽  
pp. 45-52 ◽  
Author(s):  
Abayomi Ajayi ◽  
Titilayo Ige ◽  
Nich Arawa Ude ◽  
Olusegun Dare Omotoso ◽  
Gbenga Olorunshola Alege ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Aqueous Extract ◽  
Prostatic Hyperplasia ◽  
Vernonia Amygdalina ◽  
Histological Changes ◽  
Prostate Enlargement ◽  
Urinary Tract Symptoms ◽  
Ameliorative Effect ◽  
Group A ◽  
Group B

Benign prostatic hyperplasia (BPH) is an age-dependent condition involving prostate enlargement which may lead to lower urinary tract symptoms (LUTS). This study was designed to study the ameliorative effect of the aqueous extract of bitter leaf Vernonia amygdalina Delile (Asterales: Asteraceae) on testosterone-induced BPH in a rat model. Thirty adult male Wister rats were randomly divided into six groups (A to F), with BPH induced through a single subcutaneous injection of 5 mg/kg of testosterone propionate (TP) and Vernonia amygdalina administered in various doses through oral gavage for 14 days. Group A (control) was administered with distilled water only, group B with 5 mg/kg of TP only, group C with 5 g/mL of V. amygdalina only, group D with 5 mg/kg of TP and 5 g/mL of V. amygdalina, group E with 5 mg/kg of TP and 7.5 g/mL of V. amygdalina and group F with 5 mg/kg of TP and 10 g/ml of V. amygdalina. Results show that testosterone caused histological changes that are similar to the presentation of BPH in the prostate. Aqueous extract of V. amygdalina was observed to ameliorate testosterone-induced histological changes and prostatic parameters especially at higher concentration. This suggests that bitter leaf could be a candidate herb for the treatment of BPH.

scholarly journals Continuous versus Intermittent Tamsulosin Therapy in Men with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia: A Randomized Control Trial

2020 ◽  
Vol 15 (1) ◽  
pp. 22-26
Author(s):  
SM Shameem Waheed ◽  
Mohammad Abdur Rakib ◽  
Md Shahidul Islam ◽  
Mohammad Abdur Rakib ◽  
Md Ashif Chowdhury ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Benign Prostatic Hyperplasia ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Prostatic Hyperplasia ◽  
Urinary Tract Symptoms ◽  
Significant Difference ◽  
Group A ◽  
Group B ◽  
Lower Urinary

Introduction: Benign prostatic hyperplasia (BPH) is the most common benign tumour in men. About 50% of men at the age of 50 years develop BPH and about half of them report to the doctors with some form of lower urinary tract symptoms (LUTS). Objectives: To see the therapeutic effect of Tamsulosin on alternate day administration in comparison to daily dose for men who had been suffering from LUTS due to BPH. Materials and Methods: This clinical trial was carried out at Combined Military Hospital, Dhaka in a consecutive fashion for about 18 months. A total of 152 patients were selected from outpatient department and after assessing them through inclusion and exclusion criteria and grouped randomly in three groups Group-A (50 patients), Group-B (50 patients) and Group C (52 patients); all the patients were treated with Tablet Tamsulosin (0.4mg) daily for first three months. Then next 15 months they were treated as; Group-A received Tablet Tamsulosin (0.4mg) daily, Group-B received Tablet Tamsulosin (0.4mg) every alternate day and Group C received placebo Tablet (Folic acid 5 mg) daily. Data were collected at the beginning and end of 3rd month, 4th month, 7th month and 18th month of study, in the form of international prostate symptom score (IPSS), maximum urinary flow per second (Qmax) and post-voidal residue (PVR). Results: This study showed that at the initial three month, IPSS score declined in all three groups, Qmax improved and PVR reduced in all groups. In next phase of study; in Group-A patient there was progressive and significant improvement of all parameters (IPSS, Qmax and PVR) at the end of study. In Group-B patient also showed similar result at the end of study. In Group-C patient showed statistically significant difference in outcome in relation to Group-A and Group-B i.e. more in IPSS, less in Qmax and increase in PVR. Conclusion: With this study it is clearly evident that tamsulosin (0.4mg) therapy significantly improves symptoms of men suffering for LUTS due to BPH. And alternate day therapy having similar therapeutic outcome in relation to every day therapy. Journal of Armed Forces Medical College Bangladesh Vol.15 (1) 2019: 22-26

scholarly journals A Comparative Study of Efficacy and Safety Between Tamsulosin and Terazosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia

2016 ◽  
Vol 15 (1) ◽  
pp. 17-21
Author(s):  
Sakhawat Mahmud Khan ◽  
Md Matiar Rahaman Khan ◽  
Shahin Akhter ◽  
Md Mizanur Rahman
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Prostatic Hyperplasia ◽  
Common Disease ◽  
Efficacy And Safety ◽  
College Hospital ◽  
Symptomatic Benign Prostatic Hyperplasia ◽  
Group A ◽  
Group B ◽  
A Prospective Study

Background: Lower urinary tract symptoms suggestive of symptomatic Benign Prostatic Hyperplasia (BPH) are a very common disease in elderly men .The incidence of benign prostatic hyperplasia is age related.Objectives: To compare the efficacy and safety of Tamsulosin and Terazosin in the treatment of symptomatic Benign Prostatic Hyperplasia.Methods: This was a prospective study carried out in the Department of Urology, Chittagong Medial College Hospital, Chittagong, Bangladesh during the period of July to December 2014. Total 40 patients of 45-80 years of age were consequently selected according to inclusion criteria. After completion of baseline clinical evaluation and investigations, participants were divided into two groups, group A and group B. Group A (n=20) was given Terazosin 1mg daily for 3 days at bed time and then 2 mg daily at bed time for 2 months. Group B (n=20) was given Tamsulosin, 0.4 mg per day for 2 months. Efficacy was evaluated of each group after 2 month follow up and lastly a comparison was made between them. The parameters monitored were International Prostate Symptoms Score (IPSS) Maximum urine flow rate (Qmax) and Post Voidal Residual Volume (PVR). Tamsulosin 0.4 mg and Terazosin 2 mg once daily for 8 weeks both are effective in relieving symptoms of BPH but Tamsulosin is superior to Terazosin in improvement of total IPSS (p<0.001) and Qmax (p<0.01) PVR (p<0.01) at the end point.Results: Outcome of parameters at follow up after 2 months. Tamsulosin group showed significant improvement of IPSS (p<0.05) PVR (p<0.001) and Qmax (p<0.001) than Terazosin. The incidence of adverse events by administration of Tamsulosin was less than that by Terazosin.Conclusion: Tamsulosin appears to have more efficacy and safety than Terazosin in symptomatic BPH.Chatt  Shi Hosp Med Coll J; Vol.15 (1); Jan 2016; Page 17-21

scholarly journals PROSTATIC HYPERPLASIA;

2017 ◽  
Vol 24 (10) ◽  
pp. 1560-1565
Author(s):  
Muhammad Sheraz Javed ◽  
Safdar Hassan Javed
Keyword(s):  
Prostatic Hyperplasia ◽  
Significant Response ◽  
Age Group ◽  
Urinary Tract Symptoms ◽  
Prostate Size ◽  
Group A ◽  
Male Patients ◽  
Comparative Results ◽  
Group B ◽  
Lower Urinary

Lower Urinary Tract Symptoms. Alpha-1 adrenoceptor antagonists are mostfrequently prescribed medical management for LUTS and among these tamsulosin andterazosin are the most common. Objectives: To access comparison of efficacy of tamsulosinand terazosin for management of LUTS due to prostatic hyperplasia in terms of InternationalProstate Symptom Score (IPSS). Place and duration: Study being conducted at Departmentof Urology and Kidney Transplantation, Allied Hospital, Faisalabad for period of 24 months from01-07-2014 to 30-06-2016. Methodology: 659 male patients enrolled in study and randomlyassigned to Group A (Patients being administered with tamsulosin) and Group B (Patients beingadministered with terazosin) and improvement in IPSS monitored over period of two weeks.Results: 659 patients enrolled with mean age+sd as 61.9+10.2 years. Group A includes 330patients while Group B include 329 patients. Among Group A, 250 patients showed significantimprovement in IPSS while in Group B, 215 patients showed significant response to medicalmanagement in terms of IPSS and both groups showed statistically comparative response.Statistical response of management also determined in terms of variables of IPSS severity,prostatic size and age of patient and found that efficacy of the two groups were statisticallycomparable for patients with mild IPSS while in patients with moderate IPSS has response totreatment with tamsulosin but no statistical association of efficacy for treatment with terazosin.No statistical response was found for improvement in symptoms in cases with severe IPSS ineither groups. When response monitored in terms of prostate size in both groups, it was foundthat both groups have statistical response when prostate size is less than 35 grams, between35-55 grams but in case when prostate size was more than 55 grams, no statistical responsewas found with group B patients. When response was measured in terms of variable of age,results were consistent with the fact that statistically significant response of efficacy was foundin either groups for age group 45-55 years and 56-65 years but no statistical response wasfound for Group B when considered for age group more than 65 years. Conclusion: Based onresults it is concluded that both tamsulosin and terazosin has got comparative results in overallresponse. However, tamsulosin has superiority in treatment when IPSS is moderate, prostatesize is more than 55 grams and age of patient is more than 65 years.

scholarly journals Impact of benign prostatic hyperplasia surgical treatment on voiding and urinary bladder filling symptoms

2010 ◽  
Vol 67 (1) ◽  
pp. 55-58
Author(s):  
Snjezana Milicevic ◽  
Dusko Vasic
Keyword(s):  
Surgical Treatment ◽  
Benign Prostatic Hyperplasia ◽  
Urinary Bladder ◽  
Prostatic Hyperplasia ◽  
Time Intervals ◽  
Bladder Filling ◽  
Voiding Symptoms ◽  
Group A ◽  
Group B ◽  
Variation Interval

Background/Aim. Benign prostatic hyperplasia (BHP) is one of the most common diseases of elderly men. The aim of this study was to evaluate the effect of surgical treatment of benign prostatic hyperplasia to voiding and urinary bladder filling symptoms. Quantification of voiding and filling symptoms was done with the International Prostate Symptom Score (IPSS). Method. The study included 80 patients with BHP, of whom 40 were treated with open prostatectomy (group A), and other 40 with transurethral resection of prostate gland (group B). All the patients were under 80 years old (average age in the group A was 70.23 years with a variation interval of 21 years, and in the group B 69.37 years with a variation interval of 22 years), with a value of IPSS > 19 points, quantity of residual urine higher than 150 mL, the weight of benign prostatic gland hyperplasia tissue over 30 grams for the method of prostate transurethral resection, and over 80 grams for the method of open prostatectomy. To all patients, for two times, the value of IPSS was determined, and then in a postoperative period in time intervals of 4 and 12 weeks. Results. Arithmetic mean of IPSS preoperatively was 32.05 points in the group A and 31.75 points in the group B. During the postoperative check-ups in time intervals of 4 and 12 weeks, arithmetic means of IPSS in the group A were 5.4 and 1.85 points, respectively, and in the group B 11.425 and 9.025 points, respectively. Surgical treatment had better effect on voiding symptoms than on urinary bladder filling ones. Conclusion. After the mentioned surgical procedures a significant reduction of the lower urinary tract symptoms quantified by the IPSS was observed. Surgical treatment of BHP had a more pronounced effect on the voiding symptoms in relation to filling ones.

Ameliorative effect of aqueous extract of bitter leaf on egg yolk induced kidney toxicity in adult wistar rats

2017 ◽  
Vol 2 (2) ◽  
pp. 25
Author(s):  
Richard Agbonluai Ehimigbai
Keyword(s):  
Aqueous Extract ◽  
Wistar Rats ◽  
Egg Yolk ◽  
Wistar Rat ◽  
Normal Diet ◽  
Kidney Toxicity ◽  
Ameliorative Effect ◽  
Group A ◽  
Vascular Obstruction ◽  
Group B

ABSTRACT The aim of the study is to assess the effect of aqeueous extract of  bitter leaf on egg yolk induced kidney toxicity in adult wistar rat. A total of 44 (forty four) adult wistar rats weighing between 220 g to 250 g were separated into 4 groups of 11 rats per group. Group A rats were placed on normal diet only while Group B rats received 300 mg/ kg body weight / day (BWT/D) of egg yolk. Group C rats received 250mg / kg BWT/D of bitter leaf. Group D rats received 300 mg/ kg BWT/D of egg yolk and 250mg / kg BWT/D of bitter leaf. The dosage were given for 32 days via orogastric method. The biochemical outcome showed that group B revealed marked elevation in the urea, SOD, cholesterol level when compared with the other groups. Histologically, group B showed a mild vascular obstruction and patchy tubular necrosis, while group A, C and D revealed normal architecture of the kidney. We can therefore concluded that the aqueous extract of bitter leaf have antioxidative and neproprotective properties against egg yolk induced kidney toxicity in wistar rat.

Sign in / Sign up

Export Citation Format

Share Document